SCHEMBL4451887

SCHEMBL4451887

Nc1c(C(=O)O)cnn1CCc1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.56
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
GRN P28799 1/20 0.44
SORT1 Q99523 1/20 0.44
TSHR P16473 2/20 0.43
HPGD P15428 1/20 0.42
ACLY P53396 1/20 0.41
RIPK2 O43353 1/20 0.41
ADORA1 P30542 3/20 0.41
MCL1 Q07820 1/20 0.40
BCL2A1 Q16548 1/20 0.40
ADORA2A P29274 2/20 0.40
ADORA3 P0DMS8 1/20 0.40
KDM6B O15054 1/20 0.40
KDM4C Q9H3R0 1/20 0.40
NPC1 O15118 1/20 0.39
LMNA P02545 1/20 0.39
MAPK14 Q16539 1/20 0.39
NR4A3 Q92570 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27533039 0.84 ALDH1A1 (0.76) ALDH1A1MEN1KMT2ATSHRHPGD
SCHEMBL6052327 0.82 SMN1; SMN2 (0.47) ALDH1A1MEN1KMT2AGRNSORT1
SCHEMBL4599422 0.79 ALDH1A1 (0.44) ALDH1A1MEN1KMT2ATSHRRIPK2
Hydrochloric Acid SCHEMBL5424757 0.78 ALDH1A1 (0.43) ALDH1A1MEN1KMT2ATSHRRIPK2
SCHEMBL28036519 0.75 MAPK14 (0.46) ALDH1A1NPC1LMNAMAPK14
SCHEMBL17023218 0.74 KDM4C (0.41) ALDH1A1GRNSORT1ACLYKDM6B
SCHEMBL7811465 0.74 MAPK14 (0.43) MAPK14
SCHEMBL27758253 0.74 ALDH1A1 (0.43) ALDH1A1KMT2ATSHRHPGDKDM4C
SCHEMBL174541 0.74 TSHR (0.76) ALDH1A1TSHRHPGDRIPK2NPC1
SCHEMBL2806923 0.74 ALDH1A1 (0.45) ALDH1A1KMT2ATSHRHPGDNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7629349-B2 Pyrazolo [3,4-d] pyrimidine derivatives and their use as purinergic receptor antagonists VERNALIS RESEARCH LIMITED (GB) 2009-12-08 US disclosed
EP-1349552-B1 PYRAZOLO[3,4-d]PYRIMIDINE DERIVATIVES AND THEIR USE AS PURINERGIC RECEPTOR ANTAGONISTS VERNALIS RES LTD (GB) 2008-08-20 EP disclosed
US-7087754-B2 Pyrazolo[3,4-d]pyrimidine derivatives and their use as purinergic receptor antagonists VERNALIS RESEARCH LIMITED (GB) 2006-08-08 US disclosed
US-20060111373-A1 PYRAZOLO [3,4-D] PYRIMIDINE DERIVATIVES AND THEIR USE AS PURINERGIC RECEPTOR ANTAGONISTS VERNALIS RESEARCH LIMITED 2006-05-25 US disclosed
US-20040116447-A1 Pyrazolo[3,4-d]pyrimidine derivatives and their use as purinergic receptor antagonists VERNALIS RESEARCH LIMITED (GB) 2004-06-17 US disclosed
EP-1349552-A1 PYRAZOLO 3,4-D]PYRIMIDINE DERIVATIVES AND THEIR USE AS PURINERGIC RECEPTOR ANTAGONISTS VERNALIS RESEARCH LIMITED (GB) 2003-10-08 EP disclosed
WO-2002055082-A1 PYRAZOLO[3,4-D]PYRIMIDINE DERIVATIVES AND THEIR USE AS PURINERGIC RECEPTOR ANTAGONISTS VERNALIS RESEARCH LIMITED (GB) 2002-07-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060111373-A1 PYRAZOLO [3,4-D] PYRIMIDINE DERIVATIVES AND THEIR USE AS PURINERGIC RECEPTOR ANTAGONISTS CHRNA6, CHRNA5, CNR1 ALDH1A1 2224/4885MEN1 4868/4885KMT2A 3309/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.